Hillerød, Denmark

Denmark is a world leader in biopharmaceutical development with robust commercial pipelines of biopharmaceuticals in clinical development.

When current expansions are complete in 2026, Hillerød will be home to the largest end-to-end cell culture CDMO in Europe nestled in the countryside, 37 km from Copenhagen.  With the $1.6 billion (11 billion Danish Kroner) investment announced in 2022, the site will offer a total of 20 X 20,000 L bioreactors for drug substance production complemented by comprehensive drug product and finished goods services.


Our team knows what it is like to lean into innovation with the wind of expertise, experience and passionate dedication at our backs.  We know what it takes to continuously produce advanced biologics, and we know the value each person brings to the team.  Our multinational team fosters an environment rich with diverse perspectives, and when this is combined with common purpose and shared values, they propel us to tremendous success.


Known for its history, culture, and beautiful nature, Hillerød is located in the heart of North Sealand – and the Danish life science cluster.  It is recognized as a vital regional center and transportation hub, and it is well connected with railway stations.  Steeped in history and culture, the beautiful countryside boasts majestic beech forests, offering a serene and picturesque environment.  


Our global climate strategy, Partners for the Planet, began with efforts from the passionate team in Denmark.  Known as one of the world’s most sustainable countries, it was only natural for our team to champion our organization’s goals for reductions in GHG emissions, water use management and waste reduction.

One of our crowning achievements culminated in the Power Purchase Agreement signed with Better Energy recently for an off-site solar park in Vedde.  In July 2025, this park is expected to cover the total electricity consumption for current and new operations coming online in 2024.